Aldevron to Expand mRNA Production Capability

Kadeja Johnson
9 May 2023
SHARE NOW
Collaborations, Mergers & Acquisitions
GMP
Leading global manufacturer of high-quality plasmid DNA, RNA and proteins used in cell and gene therapies and vaccine development, Aldevron, will include lipid nanoparticle (LNP) encapsulation and aseptic fill-finish capabilities expanding its mRNA production capabilities

Aldevron, a Danaher Corporation company, is partnering with Precision Nanosystems (PNI) and Cytiva, also Danaher operating companies. The expansion will provide Aldevron’s customers with the ability to efficiently manage clinical and commercial mRNA programs leveraging PNI’s LNP formulation expertise, and featuring Cytiva’s SA25 aseptic filling workcell.

Kevin Ballinger, President of Aldevron explained that the: “collaboration will help to bring innovative and life-saving therapies to patients faster. By working with PNI and Cytiva, Aldevron can capitalize on their expertise to build a streamlined service for the development, production and release of mRNA drug substance and drug product.”

Aldevron supports thousands of scientists who are developing revolutionary, lifesaving treatments for millions of people.

“Leveraging the collective strength that includes Cytiva, Precision Nanosystems and valued external partners, Aldevron will provide a complete solution for mRNA development within a single workflow and quality system,” added Mark Wetzel, Vice President/General Manager of mRNA Services.

How are you enjoying this news article? Let us know your thoughts, here >>

 

The new capability will support the production of therapeutic-scale clinical and commercial-stage mRNA therapies for cancer, genetic disease and clinical-stage vaccines for infectious diseases. It will also reduce the lead times with less project overhead, the aim will be to create a range of streamline, improved flexible yet simple mRNA programs for its customers.

Wetzel emphasized:

“Danaher’s best-in-class scientific and technical expertise, our goal is to compress the timeframes needed in therapy development and commercialization to accelerate the delivery of innovative mRNA therapies to patients.”

“Danaher is a global science and technology innovator committed to helping its customers solve complex challenges and improving quality of life around the world,” Wetzel continued

Source: Aldevron Press Release


While we have you…

We are continuously working to better optimize our content for you, our audience. Let us know how we’re doing by ticking the box below, or send us your feedback directly to team@phacilitate.com.